Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03879824
Other study ID # 2611
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 30, 2019
Est. completion date January 20, 2021

Study information

Verified date January 2021
Source Carilion Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The R-TAVI study is a randomized pilot study examining the use of the right radial artery versus the femoral artery for secondary vascular access during transcatheter aortic valve implantation (TAVI).


Description:

The R-TAVI study is a prospective, single institution, pilot study in which eligible TAVI patients will be randomized pre-procedurally to receive either secondary radial artery (RA) access or femoral artery (FA) access during TAVI. Our study will take place over a projected 18 month enrollment period.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date January 20, 2021
Est. primary completion date January 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1) Patient meets eligibility for TAVR as decided upon by pre-TAVR testing (Echo, cardiac catheterization, CTA TAVR, 2 CT surgical consults, heart team discussion). 2) Undergoing TAVR procedure and follow-up at Carilion Clinic Cardiology Roanoke Memorial Hospital (CRMH) 3) Patient's secondary vascular access can be performed femorally OR radially, as determined by TAVR operator after review of pre-TAVR CT scan imaging. 4) Interventional Cardiologist performing the TAVR agrees to consider patient for enrollment. 5) Patient provides consent 6) Age = 18 years old 7) No evidence of precluding arterial disease of both femoral arteries 8) No evidence of precluding arterial disease of right radial and subclavian arteries 9) Must have palpable pulses in both radial arteries Exclusion Criteria: 1. Review of pre-TAVR CT scan imaging deems patient unsuitable for radial OR femoral secondary access based on presence of excessive calcification, stenosis, or tortuosity of the femoral, subclavian, or innominate arteries. 2. Valve implantation (primary access) planned via alternative vascular access (trans-caval, axillary, carotid, direct aortic, trans-apical)-as determined by implanting Interventional Cardiologist/TAVR operator. 3. Prior coronary artery bypass graft surgery in which a radial artery graft was harvested and used as a conduit. 4. Patients on hemodialysis OR with arteriovenous fistulas. 5. Interventional Cardiologist performing the TAVR declines patient consideration in the study. 6. Patient declines consent. 7. Urgent or emergent TAVI cases 8. Patient is already participating in another clinical research study

Study Design


Intervention

Procedure:
Secondary Radial Artery Access
Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
Secondary Femoral Artery Access
Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.

Locations

Country Name City State
United States Carilion Clinic Roanoke Virginia

Sponsors (1)

Lead Sponsor Collaborator
Carilion Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients who Develop Death, MI, Stroke, and ACUITY major bleeding from the start of the TAVI procedure until hospital discharge We will report the number of patients who develop death, myocardial infarction, stroke, and/or ACUITY major bleeding definitions from the start of the TAVI procedure to the the time of patient's hospital discharge after undergoing the TAVI procedure.
The time of hospital discharge ranges from 24 -72 hours after TAVI procedure, depending on the patient's course of recovery.
This will be reported as a composite incidence of death, MI, stroke and ACUITY major bleeding.
At time of hospital discharge (ranges from 24 hours post procedure - 72 hours post procedure)
Primary Number of Patients who Develop Death, MI, Stroke, and ACUITY major bleeding within 30 days post TAVI procedure We will report the number of patients who develop death, myocardial infarction, stroke, and/or ACUITY major bleeding definitions from the start of the TAVI procedure to the the time of their 30-day post TAVI follow up
This will be reported as a 30-day composite incidence of death, MI, stroke and ACUITY major bleeding.
Procedure start to 30-day follow-up.
Secondary Number of patients who successfully undergo completion ileofemoral angiography of the valve implantation access site via the randomized secondary arterial access site Intra-procedural metric
Secondary Number of patients who underwent successful endovascular intervention to the valve implantation ileofemoral access site via the randomized secondary access point Intra-procedural metric
Secondary Radiation Dose (in minutes of fluoroscopy time) Intra-procedural metric
Secondary Radiation Dose (in milligrays, mGy) Intra-procedural metric
Secondary Procedure Start-Stop Time (minutes) Intra-procedural metric
Secondary Number of patients requiring conversion to secondary femoral access from secondary radial access Intra-procedural metric
Secondary Number of patients who developed a major vascular complications, as defined by the 2nd Valve Academic Research Consortium (VARC-2) Criteria from the start of the TAVI procedure until hospital discharge The time of hospital discharge ranges from 24 -72 hours after TAVI procedure, depending on the patient's course of recovery. At time of hospital discharge (ranges from 24 hours post procedure - 72 hours post procedure)
Secondary Number of patients who developed a major vascular complications, as defined by the 2nd Valve Academic Research Consortium (VARC-2) Criteria within 30 days post TAVI procedure At 30 Day Follow-Up
Secondary Number of patients who developed a minor vascular complications, as defined by the 2nd Valve Academic Research Consortium (VARC-2) Criteria from the start of the TAVI procedure until hospital discharge The time of hospital discharge ranges from 24 -72 hours after TAVI procedure, depending on the patient's course of recovery. At time of hospital discharge (ranges from 24 hours post procedure - 72 hours post procedure)
Secondary Number of patients who developed a minor vascular complications, as defined by the 2nd Valve Academic Research Consortium (VARC-2) Criteria within 30 days post TAVI procedure At 30 Day Follow-Up
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Completed NCT01676727 - ADVANCE Direct Aortic Study
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A